GBT
ALXN

Grove Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Grove Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-865
Closed -$103K – 490
2017
Q4 		$103K Sell
865
-379
-30% -$46.2K 0.05% 215
2017
Q3 		$175K Sell
1,244
-103
-8% -$14K 0.09% 170
2017
Q2 		$164K Buy
1,347
+890
+195% +$104K 0.1% 148
2017
Q1 		$55K Buy
457
+390
+582% +$50.3K 0.05% 203
2016
Q4 		$8K Buy
+67
New +$8.2K 0.01% 395

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grove Bank & Trust's ALXN Position: Q1 2018 in Review

Grove Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 865 shares — an estimated $103K sold.

Grove Bank & Trust first reported a position in ALXN in Q4 2016 and held it in 5 quarters. The position peaked at $175K in Q3 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Grove Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Grove Bank & Trust sold 865 Alexion Pharmaceuticals shares in Q1 2018, an estimated $103K.
  • Grove Bank & Trust first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Grove Bank & Trust's Alexion Pharmaceuticals position peaked at $175K in Q3 2017.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Grove Bank & Trust's 13F filing for Q1 2018, filed 7 May 2018.